REDWOOD CITY, Calif. April 7, 2014 - OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical- stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced data from an oral presentation and eight poster presentations at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA April 5-9, 2014. The research presented at AACR highlighted OncoMed’s drug discovery platforms along with preclinical and biomarker discoveries on its clinical-stage product candidates and several emerging product candidates. A brief summary of each presentation is provided below.
“The nine presentations at this year’s AACR Annual Meeting demonstrate the breadth and depth of OncoMed’s preclinical research and discovery work. Encompassing many of our clinical and preclinical stage candidates, data being presented this week highlight the potent anti-cancer stem cell activity seen across our portfolio, the opportunities to combine our compounds with standard-of-care, and our ongoing biomarker identification efforts being applied to programs in clinical development,” said John Lewicki, PhD, Executive Vice President, Chief Scientific Officer.
Read More: http://www.vertical-group.com/uploads/1/3/9/6/13963771/omed_aacr_press_release_2014_v5.pdf
OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting